The potential of precision medicine is “unprecedented” and represents “a turning point in medicine,” according to cardiologist and geneticist Eric Topol and as reported in the lead article on our integrated care blog last month.

In a recent interview with the US STAT magazine, Topol, who serves as Director of the Scripps Translational Science Institute (STSI), said the data will help to improve prevention and treatment efforts on a much more personalised level. He called current testing “a profound waste” that proliferates “one-size-fits-all” efforts.

“This is a new day,” Topol says. “This is a reset, a reboot of what we thought about medicine - and it’s all predicated on what we know about individual people.”

In future, biosensors, he says, will help to determine “truly normal blood pressure,” with measures taken in real-world settings such as in traffic.

The Scripps Research Institute in La Jolla, California, where Topol serves as a professor of genomics, was awarded a National Institutes of Health (NIH) grant this month of close to $120m (approx. €108m) over five years for its role in the Precision Medicine Initiative. The grant, according to an announcement, will support a Participant Technologies Center through STSI that will be key to enrolment efforts in the program.

Read the full article here – Precision medicine will revolutionise healthcare

Related News

COCIR and SIA launch ID recommendations

A new joint publication, launched at the HIMSS Europe and Health 2.0 Conference, gives critical guidance on the identity challenge facing healthcare
HSCIC, Integrated Care

UK’s 1.2 million data opt-out

UK e-Health Week

Future of young people in hands of eHealth, says health leader